Effect brexpiprazole augmentation for aripiprazole one-monthly on cognitive functioning in Japanese schizophrenia: A Randomized Controlled Clinical Trial
Not Applicable
- Conditions
- schizophrenia
- Registration Number
- JPRN-UMIN000043576
- Lead Sponsor
- Department of Neuropsychiatry, Kansai Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Serious complication Active suicidal ideations or past suicide attempts Drug or alcohol abuse Pregnant or breast-feeding females mental retardation Using of oral aripiprazole or asenapine, blonanserin Having been judged as unsuitable for the study forin other reasons by an principal investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in Brief Assessment of Cognition in Schizophrenia (BACS) composite scores from week 0 to week 24
- Secondary Outcome Measures
Name Time Method Remission rate, Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression-Severity scale (CGI-S), Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS), UKU Side Effect Scale(UKU), Barnes Akathisia Rating Scale (BARS), Epworth Sleepness Scale(ESS), body weight, Body Mass Index, blood biochemistry, Japanese Adult Reading Test (JART), electroencephalography